Among the features that distinguish type 1 innate lymphoid cells (ILC1s) from natural killer (NK) cells is a gene signature indicative of 'imprinting' by cytokines of the TGF-b family. We studied mice in which ILC1s and NK cells lacked SMAD4, a signal transducer that facilitates the canonical signaling pathway common to all cytokines of the TGF-b family. While SMAD4 deficiency did not affect ILC1 differentiation, NK cells unexpectedly acquired an ILC1-like gene signature and were unable to control tumor metastasis or viral infection. Mechanistically, SMAD4 restrained non-canonical TGF-b signaling mediated by the cytokine receptor TGFbR1 in NK cells. NK cells from a SMAD4-deficient person affected by polyposis were also hyper-responsive to TGF-b. These results identify SMAD4 as a previously unknown regulator that restricts non-canonical TGF-b signaling in NK cells.
Natural killer (NK) cells are a major innate source of interferon-γ (IFN-γ) during immune responses to virus-infected cells and tumor cells 1 . Additional subsets of innate lymphoid cells (ILCs) that produce IFN-γ have been identified and have been collectively designated 'type 1 ILCs' (ILC1s). However, the criteria used to distinguish ILC1s from NK cells and the relationship between the two cell types remain somewhat controversial. On the basis of ontogeny, mouse NK cells and ILC1s are thought to derive from developmentally distinct, restricted progenitor cells that branch from the shared common innate lymphoid progenitor cell that gives rise to all ILCs [2] [3] [4] [5] [6] [7] . Downstream of that progenitor cell, one branch leads to generation of the NK cell progenitor, which subsequently differentiates into mature NK cells, a path that requires the transcription factors T-bet and Eomes. Another branch includes progenitor cells with progressively restricted potential that culminate in the generation of T-bet-dependent and Eomesindependent ILC1s, as well as other ILC subsets that produce the cytokines IL-5 and IL-13 (ILC2s) or IL-17 and IL-22 (ILC3s) [3] [4] [5] [6] [7] . While committed ILC-precursor cells capable of giving rise to all ILC populations in humans have been identified, whether human counterparts of mouse T-bet-dependent and Eomes-independent IFN-γ-producing ILC1s exist is matter of debate [8] [9] [10] .
Another criterion used to distinguish NK cells from ILC1s is based on mobility and location: NK cells recirculate throughout lymphoid organs, whereas ILC1s are found as resident cells in non-lymphoid tissues, such as the gut, liver, adipose tissue and salivary glands (SGs). In mice, tissue residency of ILC1s has been demonstrated by parabiosis [11] [12] [13] and is possibly implemented by the constitutive expression of a specialized set of molecules, including the integrins CD49a (α 1 ) and CD103 (α E β 7 ) and the activation marker CD69 (refs. 11-15) . It has been shown that the development of tissue-resident ILC1s is driven in part by the transcription factor Hobit 16 . Accordingly, Hobitdeficient mice lack liver CD49a + ILC1s. Human counterparts of mouse tissue-resident ILC1s are present within the epithelium of the oral and intestinal mucosae 14 .
Finally, ILC1s and NK cells have been distinguished in mice on the basis of their transcriptome profiles 3, 17, 18 . In addition to Itga1 (which encodes CD49a), the ILC1 gene signature includes the expression of genes that encode the cytokine receptors IL-7R and IL-21R, the death-inducing molecule TRAIL and the AMP-degrading enzyme CD73, as well as germline transcripts Trvg2 and Tcrg-V3 (which encode γ-chain variable regions of the T cell antigen receptor). The defining signature of NK cells includes the expression of genes that encode the integrin CD49b (α 2 ) and inhibitory receptors for major histocompatibility complex class I, as well as Eomes, but essentially no expression of the gene encoding IL-7R. A subset of ILC1s in the SGs has been described that has the phenotype of both ILC1s and NK cells 15 . Like ILC1s, SG ILC1s express CD49a, CD103, TRAIL, CD73, IL-21R and Hobit. Similar to NK cells, SG ILC1s also express CD49b, T-bet and Eomes but lack IL-7R. However, in contrast to other ILC1s, SG ILC1s are weak producers of IFN-γ. These observations suggest that ILC1s might include a spectrum of cells with partially overlapping phenotypes and functions that vary depending on the tissue microenvironment.
Among various tissue factors, cytokines of the TGF-β family are emerging as crucial mediators in the differentiation of ILC1s. These cytokines transmit intracellular signals by forming a hetero-tetrameric A r t i c l e s receptor complex with two type I receptors and two type II receptors 19 . Type II receptors activate type I receptors, which are the main propagators of intracellular signals through recruitment and phosphorylation signal transducers collectively known as 'R-SMAD' ('receptor SMAD'). Phosphorylated R-SMAD pairs with SMAD4, which facilitates its translocation into the nucleus to initiate the transcription of hundreds of genes. Alternatively, the E3 ubiquitin ligase TRIM33 can compete with SMAD4 for binding to phosphorylated R-SMAD, and this complex mediates the transcription of a distinct set of genes 20 . Finally, cytokines of the TGF-β family can activate many other signal transducers, such as the kinases MAPK and PI(3)K via non-canonical R-SMAD-independent pathways, some of which remain poorly defined 21 .
Published studies have shown that ablation of the type II TGF-β receptor TGFβR2 in SG ILC1s abolishes expression of CD49a, CD103, TRAIL and CD73 while enhancing both the expression of Eomes and the ability to produce IFN-γ 13 . However, lack of TGFβR2 has little or no effect on gut or liver ILC1s, which suggests that other cytokines of the TGF-β family, such as bone-morphogenic proteins and activin proteins, might drive the differentiation of precursor cells into ILC1s in these tissues. Here we further pursued this hypothesis by generating mice in which both ILC1s and NK cells selectively lack SMAD4, which promotes canonical signaling by all cytokines of the TGF-β family. We expected SMAD4 deficiency to block ILC1 differentiation in all tissues. Moreover, given the reported inhibitory effect of TGF-β on the development and function of NK cells [22] [23] [24] , we anticipated that a lack of SMAD4 in NK cells would enhance their function. In contrast, we found that SMAD4 deficiency did not visibly affect ILC1 differentiation but instead altered the phenotype of conventional NK cells: SMAD4-deficient NK cells had a gene signature that was ILC1-like and was indicative of imprinting by TGF-β. SMAD4 deficiency affected the control of tumor metastasis and viral infection by NK cells by affecting both the function and proliferative capacity of these cells. SMAD4 served an essential function in curtailing the imprinting of NK cells by TGF-β by inhibiting non-canonical signaling through TGFβR1. Notably, NK cells from a SMAD4-deficient patient were also hyper-responsive to TGF-β. Our results indicate that SMAD4 unexpectedly functions as negative regulator of non-canonical TGF-β signaling in conventional NK cells.
RESULTS

SMAD4-deficient NK cells have ILC1-like characteristics
To assess the effect of cytokines of the TGF-β superfamily on ILC1 differentiation, we crossed mice carrying loxP-flanked Smad4 alleles (Smad4 f/f ) 25 with mice in which sequence encoding 'codon-improved' Cre recombinase is knocked into the gene encoding the activating receptor NKp46 (Ncr1 iCre ) 17 . Smad4 f/f Ncr1 iCre mice lack SMAD4 in all cells expressing NKp46, which include NK cells, ILC1s and NKp46 + ILC3s, as well as RORγt + ILC3s that have converted into ILC1s (also known as 'ex-ILC3s') 17 . We first assessed expression of CD49a and CD49b, which distinguishes ILC1s from NK cells in multiple tissues. ILC1s from Smad4 f/f Ncr1 iCre mice maintained high expression of CD49a in the liver, the lamina propria of the small intestine, the intraepithelium of the small intestine and the SGs, similar to Smad4 f/f mice (Fig. 1a) , which suggested that the imprinting of all ILC1s by TGF-β was SMAD4 independent. Unexpectedly, CD49b + NK cells from the spleen, blood, bone marrow (BM), lungs, liver and gut of Smad4 f/f Ncr1 iCre mice expressed much more CD49a on the cell surface than did their counterparts from Smad4 f/f mice (Fig. 1a) , which suggested that SMAD4 deficiency induced the conversion of NK cells into ILC1-like cells.
Further comparison of global gene expression in splenic NK cells from Smad4 f/f Ncr1 iCre mice with that of such cells from Smad4 f/f mice revealed that SMAD4-deficient NK cells expressed genes such as Itga1 (which encodes CD49a), Nt5e (which encodes CD73), Tnfsf10 (which encodes TRAIL), Il21r (which encodes IL-21R), Zfp683 (which encodes Hobit) and Tsc22d1 (which encodes the transcription factor Tsc22d1), and Inpp4b (which encodes the phosphatase Inpp4b), whose expression is characteristic of ILC1s but not of NK cells (Fig. 1b and Supplementary Fig. 1a) . The expression of some ILC1 markers was confirmed by flow cytometry and RT-PCR analysis of freshly isolated SMAD4-deficient NK cells (Fig. 1c,d ), but surface expression of TRAIL became apparent only after in vitro culture of SMAD4-deficient NK cells with IL-2 (Fig. 1e) . The similarity of SMAD4-deficient NK cells to all ILC1s was further emphasized by the expression of germline Trvg2 and Tcrg-V3 transcripts (Fig. 1b) , which have been noted to be part of the ILC core signature 18 . SMAD4-deficient NK cells also had lower expression of some markers that are normally expressed on mature NK cells, such as Ly6C, CX3CR1, CD62L, KLRG1 and MCAM, than that of Smad4 f/f NK cells (Fig. 1b,f and Supplementary Fig. 1b) ; however, they retained other features typical of NK cells, including expression of both Eomes and T-bet, along with lack of expression of IL-7R and CD69 ( Supplementary  Fig. 1c ). Similar numbers of NKp46 + ILC3s were present in Smad4 f/f Ncr1 iCre mice and Smad4 f/f mice, and SMAD4-deficient NKp46 + ILC3s were functionally equivalent to their Smad4 f/f counterparts ( Supplementary Fig. 1d,e) , which indicated that NKp46-driven deletion of SMAD4 affected mainly NK cells.
We sought to determine whether SMAD4 deficiency affected NK cell development in the BM. NK cells normally differentiate from immature NKp46 − cells, with detectable expression of CD49a on the cell surface, into mature NKp46 + CD49a − cells. While immature NK cells appeared to be similar in Smad4 f/f mice and Smad4 f/f Ncr1 iCre mice, mature SMAD4-deficient NK cells had substantial upregulation of CD49a in parallel with the deletion of Smad4 by the NKp46-driven iCre (Fig. 1g) . A similar result was obtained for BM NK cells from Smad4 f/f Il7r Cre mice (Supplementary Fig. 1f) , in which Smad4 is deleted in the common lymphoid progenitor cell. Overall, these data suggested that imprinting of SMAD4-deficient cells by TGF-β occurred at a late stage of NK cell development. We concluded that lack of SMAD4 biased conventional NK cells toward an ILC1-like phenotype that most closely resembled that of SG ILC1s due to coexpression of markers of NK cells (Eomes and CD49b) and ILC1s (T-bet, CD49a and TSC22d1) (Fig. 1h) .
SMAD4 deficiency impairs NK cell control of metastatic melanoma
To assess the effect of SMAD4 deficiency on NK cell function in vivo, we chose the B16 mouse melanoma model, since the containment of B16 lung metastases is highly dependent on NK cells through the production of IFN-γ and, to a lesser extent, the release of lytic granules 26 . We injected with 1 × 10 5 B16 cells intravenously into Smad4 f/f and Smad4 f/f Ncr1 iCre mice and assessed their lungs for pulmonary metastatic nodules after 15 d. Gross and microscopic examination of the lungs revealed that Smad4 f/f Ncr1 iCre mice had a much greater burden of B16 nodules than that of their Smad4 f/f littermates (Fig. 2a,b) . The lungs of Smad4 f/f Ncr1 iCre mice had an average of 600 B16 foci per whole lung, whereas Smad4 f/f mice had approximately sixfold fewer foci (Fig. 2c) . Several Smad4 f/f Ncr1 iCre mice had too many B16 lung metastases for accurate quantification and therefore were assigned scores of the highest definite value (700 foci) (Fig. 2c) . These data demonstrated that Smad4 f/f Ncr1 iCre mice limited B16 tumor metastasis much less effectively than did Smad4 f/f mice.
A r t i c l e s
The overwhelming number of metastatic nodules present in Smad4 f/f Ncr1 iCre mice mirrored the results of studies in which NK cells are absent from the lungs 27 . Analysis of the frequency and number of NK cells revealed that these cells were present in the lungs of all mice at day 15 of the B16 tumor metastatic model, although fewer were present in Smad4 f/f Ncr1 iCre mice than in their Smad4 f/f littermates A r t i c l e s (Fig. 2d) . Moreover, Smad4 f/f Ncr1 iCre NK cells had high expression of CD49a at day 15 ( Fig. 2e) , which demonstrated that these cells maintained their ILC1-like phenotype. We concluded that SMAD4 was essential for the control of B16 lung metastasis by NK cells.
NK cell effector functions require SMAD4
To gain insight into the mechanisms underlying the impaired control of tumor metastasis in vivo, we assessed the functional capacity of SMAD4-deficient NK cells in vitro. We found that SMAD4-deficient NK cells produced significantly less IFN-γ than did Smad4 f/f NK cells in response to incubation with the cytokines IL-12 plus IL-18 or with YAC-1 mouse lymphoma cells, as target cells (Fig. 3a) . SMAD4-deficient NK cells also had impaired lytic ability after either stimulation, manifested by less CD107a on the cell surface (Fig. 3b) .
The impaired lytic ability of SMAD4-deficient NK cells was consistent with a significant reduction in the expression of Gzmb mRNA (Fig. 1b) and its product, granzyme B (Fig. 3c) . Thus, NK cells from Smad4 f/f Ncr1 iCre mice were functionally deficient compared with their Smad4 f/f counterparts.
Lack of SMAD4 alters activating and inhibitory receptors
We also assessed the expression of activating and inhibitory receptors that control the recognition of tumor cells by NK cells. SMAD4-deficient NK cells had much lower expression of the activating receptor CD226 (DNAM-1), which promotes the killing of tumor cells that express the ligands CD155 and CD112, including melanoma cells 28, 29 , than that of Smad4 f/f cells (Fig. 3d) . Conversely, SMAD4-deficient NK cells had higher expression of the inhibitory receptor TIGIT (WUCAM), which also detects CD155 and CD112 (refs. 30-33) , than that of Smad4 f/f cells (Fig. 3d) . We also noted that high TIGIT expression was a feature shared by all ILC1s (Fig. 3e) , which further confirmed the ILC1-like phenotype of SMAD4-deficent NK cells. Thus, SMAD4-deficient NK cells recognized mainly melanoma cells, as well as other tumors expressing CD155 and CD112, via the inhibitory receptor TIGIT rather than via the activating receptor CD226. In summary, the greater abundance of B16 lung metastases observed in Smad4 f/f Ncr1 iCre mice was probably due to multiple NK cell defects, including diminished functional capacity and unbalanced expression of TIGIT and CD226.
NK cell population expansion during infection requires SMAD4
In C57BL/6 mice, NK cells contain infection with mouse cytomegalovirus (MCMV) through the activating receptor Ly49H, which detects the MCMV-encoded m157 protein on infected cells; this triggers the activation, population expansion and effector function of NK cells 34 .
To determine whether SMAD4 deficiency affected the anti-MCMV response, we injected 5 × 10 4 plaque-forming units of MCMV into Smad4 f/f and Smad4 f/f Ncr1 iCre mice and monitored the mice, from day 0 through day 6 after infection, for weight loss, which reflects the severity of viral infection. Smad4 f/f Ncr1 iCre mice lost significantly more weight than did Smad4 f/f mice on days 3-6 after infection (Fig. 4a) , indicative of an impaired capacity to control MCMV infection. During A r t i c l e s the course of infection, SMAD4-deficient NK cells maintained or had enhanced expression of ILC1 markers (Fig. 4b) .
The NK cell responses of mice were further assessed at 3 d and 6 d after infection. Naive Smad4 f/f and Smad4 f/f Ncr1 iCre mice had similar numbers of splenic Ly49H + cells (Fig. 4c and Supplementary  Fig. 2a) . At day 3 after infection, differences in the frequency and number of Ly49H + and Ly49H − NK cells were observed (Fig. 4c) . The considerable population expansion of Ly49H + NK cells evident in Smad4 f/f mice at day 6 after infection was much lower in Smad4 f/f Ncr1 iCre mice (Fig. 4c) . Similarly, fewer Ly49H − NK cells, which undergo more limited population expansion during infection, were present in Smad4 f/f Ncr1 iCre mice than in Smad4 f/f mice at day 6 after infection (Fig. 4c) . These results indicated that SMAD4-deficient NK cells were defective in the ability to proliferate and/or survive during infection with MCMV.
To directly assess NK cell proliferation, we infected Smad4 f/f and Smad4 f/f Ncr1 iCre mice with MCMV and injected the thymidine analog bromodeoxyuridine (BrdU) intraperitoneally into the mice at day 3 after infection, then assessed incorporation of BrdU into NK cells 4 h later. Considerable incorporation of BrdU by NK cells, particularly the Ly49H + population, was obvious in Smad4 f/f mice, whereas much less BrdU was taken up by both Ly49H + SMAD4-deficient NK cells and Ly49H − SMAD4-deficient NK cells (Fig. 4d) . We also used expression of the proliferation marker Ki67 to assess NK cell proliferation in response to cytokine stimulation in vitro. SMAD4-deficient NK cells had significantly lower expression of Ki67 than that of Smad4 f/f NK cells (Fig. 4e) . NK cell viability during MCMV infection and in vitro culture was similar in Smad4 f/f mice and Smad4 f/f Ncr1 iCre mice (Supplementary Fig. 2b,c) . These data demonstrated that SMAD4 was critical for the population expansion of NK cells during viral infection. The failure of Ly49H + NK cell populations to expand adequately in Smad4 f/f Ncr1 iCre mice during MCMV infection contributed to the enhanced morbidity of these mice.
SMAD4 restricts TGF-b imprinting independently of TGFbR2
We hypothesized that the SMAD4-deficient NK cells were hyperresponsive to TGF-β. In support of our hypothesis, we found that Smad4 f/f and SMAD4-deficient NK cells upregulated expression of the ILC1 markers CD49a, CD73 and TRAIL when cultured in vitro with TGF-β but not when cultured with other cytokines of this family (BMP4 and activin A) (Supplementary Fig. 3 ). Since a published study has shown that imprinting of SG ILC1s by TGF-β requires TGFβR2 (ref. 13 ), we next investigated whether imprinting of SMAD4-deficient NK cells by TGF-β also depended on TGFβR2. To test that hypothesis, we generated mice that were doubly deficient in SMAD4 and TGFβR2 (Smad4 f/f Tgfbr2 f/f Ncr1 iCre ; called 'DKO' here). We confirmed that NK cells from DKO mice no longer expressed TGFβR2 ex vivo or after in vitro culture and that they were unable to engage in canonical TGF-β signaling, which requires phosphorylation of R-SMAD (Fig. 5a,b and Supplementary Fig. 4a,b) . However, NK cells from DKO mice maintained high expression of CD49a and CD73 ex vivo (Fig. 5c) and upregulated their expression of TRAIL when cultured in vitro with IL-2 (Fig. 5d) . DKO NK cells further increased their expression of TRAIL in response to TGF-β plus IL-2 (Fig. 5d) , which demonstrated A r t i c l e s that SMAD4-deficient NK cells were responsive to TGF-β even in the absence of TGFβR2. Extending that conclusion was the finding that while TGFβR2 deficiency alone affected the imprinting of SG ILC1s by TGF-β, concomitant lack of SMAD4 and TGFβR2 restored the expression of CD49a in SG ILC1s (Supplementary Fig. 4c) . Thus, the responsiveness of SMAD4-deficient NK cells and ILC1s to TGF-β was not dependent on TGFβR2.
SMAD4 inhibits a non-canonical TGFbR1-dependent pathway
We sought to determine whether deletion of receptors for the TGF-β family that transmit canonical signals through SMAD4 would be sufficient to elicit the paradoxical imprinting by TGF-β observed for SMAD4-deficient NK cells. We noticed that splenic NK cells expressed mainly type II receptors for BMPs (such as BMPR2) and TGFβR2 (Supplementary Fig. 4d ). However, NK cells deficient in Weight (%) *** *** *** *** either BMPR2 or TGFβR2 seemed to be similar to Smad4 f/f NK cells (Supplementary Fig. 4e ), which suggested that abolishing BMPR2-or TGFβR2-mediated canonical signaling was not sufficient to elicit paradoxical imprinting by TGF-β equivalent to that seen for SMAD4-deficient NK cells. We finally sought to determine whether the imprinting of SMAD4-deficient splenic NK cells by TGF-β depended on TGFβR1. To investigate this, we measured TRAIL expression on SMAD4-deficient and DKO NK cells cultured in vitro with or without SB431542, a small-molecule antagonist specific for TGFβR1. TRAIL expression was chosen because it is not detected ex vivo but becomes apparent after in vitro culture, especially in the presence of TGF-β. Therefore, TRAIL can be used as a sensitive 'read-out' of NK cell responsiveness to TGF-β. While TRAIL was expressed on the surface of cultured SMAD4-deficient and DKO NK cells and its expression was substantially upregulated by TGF-β, inhibition of TGFβR1 resulted in a dose-dependent diminution in the surface expression of TRAIL on both SMAD4-deficient NK cells and DKO NK cells (Fig. 5e,f) . No difference in cell survival was observed during this culture (Supplementary Fig. 4f ), which demonstrated that the effect of SB431542 was specific to TGFβR1 signaling. We concluded that SMAD4 restricted the imprinting of NK cells by TGF-β in a TGFβR2-independent, TGFβR1-dependent manner. 
A r t i c l e s
Human SMAD4-deficiency amplifies NK cell response to TGF-b Germline mutations in the gene encoding human SMAD4 are responsible for some cases of juvenile polyposis syndrome, an autosomal dominant disease characterized by the development of intestinal polyps and an increased risk of gastrointestinal cancer [35] [36] [37] . Thus, we sought to determine whether our finding that SMAD4 restrained the imprinting of mouse NK cells by TGF-β was applicable to human NK cells. We obtained a blood sample from a patient (PT00) affected by polyposis who has a 25-base-pair deletion in the sequence encoding the MH2 domain of SMAD4. Expression of SMAD4 protein was much lower in NK cells from PT00 than in control NK cells from healthy donors (Fig. 6a) , which confirmed that this mutation resulted in haploinsufficiency for SMAD4. We assessed the expression of CD103 and CD9, two markers that have been shown to reflect the imprinting of human ILC1s by TGF-β 14 , as well as IFN-γ production and expression of mRNA encoding Hobit. NK cells freshly isolated from the blood of PT00 did not express CD103 or CD9 (data not shown), possibly due to the remaining SMAD4 protein. However, after culture with TGF-β, NK cells from PT00 upregulated their surface expression of CD103 and CD9 much more than did NK cells from healthy donors (Fig. 6b,c) .
Moreover, NK cells obtained from PT00 and exposed to TGF-β also showed increased expression of mRNA encoding Hobit (Fig. 6c) and less production of IFN-γ after co-culture with K562 target cells (Fig. 6d) , relative to that of control NK cells from healthy donors. Together these data indicated that SMAD4 modulated the sensitivity of human NK cells to TGF-β. An excessive NK cell response to TGF-β in patients with loss-of-function mutations in the gene encoding SMAD4 might contribute to their susceptibility to colon cancer.
DISCUSSION
SMAD4 is a known positive regulator of canonical TGF-β signaling that facilitates the translocation of R-SMAD into the nucleus for the initiation of transcription. Given that TGF-β imprints ILC1s 13, 14 and impedes the development and function of NK cells 22, 23 , we anticipated that SMAD4 deficiency in these cells would promote the conversion of ILC1s into NK cell-like cells and enhance the function of differentiated NK cells. Paradoxically, ILC1s remained intact, while NK cells converted into ILC1-like cells with impaired antiviral and anti-tumor function. Despite having a defect in canonical TGF-β signaling, SMAD4-deficient NK cells were hyper-responsive to TGFβR1-mediated signals. Thus, our study has demonstrated that SMAD4 is also a negative regulator of a non-canonical TGF-β signaling pathway in NK cells. The effect of that regulatory function of SMAD4 is relevant to people with inherited defects in SMAD4, which might hamper the ability of NK cells to effectively control tumor cells and might contribute, at least in part, to their susceptibility to polyposis and colon cancer. Consistent with that, NK cells obtained from a SMAD4-haploinsufficient person had higher expression of ILC1 surface markers and less production of IFN-γ after exposure to TGF-β than that of NK cells from healthy donors. It is likely that SMAD4 deficiency in humans also affects T cell responses via a similar mechanism. In mice, selective deletion of SMAD4 in T cells results in the spontaneous formation of intestinal tumors 38, 39 and defective anti-tumor T cell responses 40 . Moreover, while TGFβR2 deficiency impairs the generation of regulatory T cells, concomitant deletion of SMAD4 in T cells offsets TGFβR2 deficiency and leads to the partial recovery of regulatory T cells in vivo 40 . Various human genetic mutations can affect SMAD4 (ref. 35); some might cause haplo-insufficiency, while others might have dominant negative effects. Future studies should establish whether a dysregulated non-canonical TGF-β pathway is engendered by all mutations in the gene encoding SMAD4 or only a portion of them.
The phenotype of TGF-β-imprinted SMAD4-deficient NK cells was notably similar to that of tissue-resident ILC1s, such as SG, intestinal and liver ILC1s. However, in the context of those studies, our results indicate that imprinting by TGF-β occurs through distinct modalities in different cell types. In SMAD4-deficient NK cells, TGF-β acts through a TGFβR1-dependent, TGFβR2-independent non-canonical pathway. In SG ILC1s, TGF-β acts through a non-canonical pathway that is TGFβR2 dependent and SMAD4 independent 13 . In other cells, such as those in the liver and gut, imprinting by TGF-β might occur through pathways that require various other members of the TGF-β or TGF-β receptor superfamilies. It will be important to define these variables in the development of the as-yet-poorly understood ILC1s, such as liver ILC1s. Future studies will also need to determine how SMAD4 restrains non-canonical TGFβR1 signaling. Among the signal transducers potentially involved in the regulation of noncanonical pathways, it is worth considering TRIM33, an E3 ligase linked to the degradation of TGFβR1 as well as to competing with SMAD4 for binding R-SMAD and inducing its translocation to the nucleus 20, 41 . The absence of SMAD4 might enhance the translocation of TRIM33-R-SMAD complexes to the nucleus while diminishing the TRIM33-mediated control of TGFβR1 in the cytosol.
Our results have identified Hobit as a key transcription factor integral to the TGF-β signature of ILC1s. Hobit is a transcription factor related to the transcription factor Blimp-1 that shapes various characteristics of tissue-resident memory T cells and liver ILC1s, particularly their ability to acquire tissue-residency features 16 . Our results demonstrated that TGF-β signaling induced Hobit and suggest that it might be a central node in the network responsible for the ILC1 functional program. Future studies should determine whether Hobit induces the expression of molecules with regulatory functions, such as CD73 and TRAIL, in addition to molecules involved in tissue residency.
ILC1s can promote anti-tumor responses in an IL-15-rich environment, which stimulates cytotoxicity 42 . Our study suggests that in TGF-β-rich tumors, ILC1s might in fact be ineffective or facilitate tumor growth because of their reduced capacity for IFN-γ production and increased expression of regulatory molecules. Accordingly, another study has shown that ILC1s found in tumors undergo strong imprinting by TGF-β and are incapable of effective anti-tumor responses 43 . Thus, the effect of ILC1s in tumors might depend on the tumor environment. We found that one common feature of ILC1s and ILC1-like cells was the expression of TIGIT, an inhibitory receptor specific for CD115 and CD112 that attenuates lymphocyte activation. Checkpointblockade strategies that target TIGIT might effectively activate ILC1s and increase anti-tumor innate immunological responses.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined. A reasonable sample size was chosen to ensure adequate reproducibility of results and was based on our previous studies.
Data exclusions
Describe any data exclusions. not applicable
Replication
Describe whether the experimental findings were reliably reproduced.
All experimental findings were reliable reproducible. All graphs displaying quantification are data pooled from multiple independent experiments.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Age and sex matched animals were used for any given experiment. Litter mate controls were also used for most experiments.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not used.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
